See what CanVECTOR members are publishing to advance the field of venous thromboembolism
Publications since 2016 that are linked to venous thromboembolism and/or anticoagulant therapy

Publications for Phil Wells

Updated daily

Back to Member List

#	PubMedId	Deleted	Publication
	37452732	0	van Es N, Takada T, Kraaijpoel N, et al. Diagnostic management of acute pulmonary embolism: a prediction model based on a patient data meta-analysis. Eur Heart J. 2023 Jul 15:ehad417. doi: 10.1093/eurheartj/ehad417.
	37121015	0	Potere N, Di Nisio M, Porreca E, et al. Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: Insights from the AVERT trial. Thromb Res. 2023 Apr 26;226:82-85. doi: 10.1016/j.thromres.2023.04.015.
	35660801	0	Brandt W, Brown C, Wang TF, et al. Efficacy and safety of apixaban for primary prevention of thromboembolism in patients with cancer and a central venous catheter: A subgroup analysis of the AVERT Trial. Thromb Res. 2022 May 29;216:8-10. doi: 10.1016/j.thromres.2022.05.014.
	34904857	0	Stals MAM, Takada T, Kraaijpoel N, et al. Safety and Efficiency of Diagnostic Strategies for Ruling Out Pulmonary Embolism in Clinically Relevant Patient Subgroups : A Systematic Review and Individual-Patient Data Meta-analysis. Ann Intern Med. 2021 Dec 14. doi: 10.7326/M21-2625.
	34715510	0	Li A, Brandt W, Brown C, et al. Efficacy and safety of primary thromboprophylaxis for the prevention of venous thromboembolism in patients with cancer and a central venous catheter: A systematic review and meta-analysis. Thromb Res. 2021 Oct 24;208:58-65. doi: 10.1016/j.thromres.2021.10.012.
	32685588	0	Peacock WF, Coleman CI, Wells P, et al. Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care. J Health Econ Outcomes Res. 2019 Oct 2;6(3):160-173. doi: 10.36469/9936. eCollection 2019.
	32433797	0	Takada T, van Doorn S, Parpia S, et al. Diagnosing deep vein thrombosis in cancer patients with suspected symptoms: An individual participant data meta-analysis. J Thromb Haemost. 2020 Sep;18(9):2245-2252. doi: 10.1111/jth.14900. Epub 2020 Jul 8.
	32333946	0	Ashley J, McArthur E, Bota S, et al. Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants. Am J Kidney Dis. 2020 Sep;76(3):311-320. doi: 10.1053/j.ajkd.2020.02.446. Epub 2020 Apr 22.
	30729377	0	Wells P, Peacock WF, Fermann GJ, et al. The value of sPESI for risk stratification in patients with pulmonary embolism. J Thromb Thrombolysis. 2019 Jul;48(1):149-157. doi: 10.1007/s11239-019-01814-z.
	29016692	0	Wang L, Baser O, Wells P, et al. Benefit of early discharge among patients with low-risk pulmonary embolism. PLoS One. 2017 Oct 10;12(10):e0185022. doi: 10.1371/journal.pone.0185022. eCollection 2017.
	28665208	0	Kohn CG, Fermann GJ, Peacock WF, et al. Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies. Curr Med Res Opin. 2017 Sep;33(9):1697-1703. doi: 10.1080/03007995.2017.1349659. Epub 2017 Jul 17.
	28652016	0	Wang L, Baser O, Wells P, et al. Overall Effectiveness of Rivaroxaban in Patients with Pulmonary Embolism. Clin Ther. 2017 Jul;39(7):1426-1436.e2. doi: 10.1016/j.clinthera.2017.06.002. Epub 2017 Jun 23.
	28421636	0	Dennis J, Medina-Rivera A, Truong V, et al. Leveraging cell type specific regulatory regions to detect SNPs associated with tissue factor pathway inhibitor plasma levels. Genet Epidemiol. 2017 Jul;41(5):455-466. doi: 10.1002/gepi.22049. Epub 2017 Apr 18.
	26547675	0	Monreal M, Mahe I, Bura-Riviere A, et al. Pulmonary embolism: Epidemiology and registries. Presse Med. 2015 Dec;44(12 Pt 2):e377-83. doi: 10.1016/j.lpm.2015.10.006. Epub 2015 Nov 4.